We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Vioxx Litigation Could Deter Drug Development, Slow Approvals, Experts Warn
Vioxx Litigation Could Deter Drug Development, Slow Approvals, Experts Warn
September 9, 2005
Pharmaceutical firms may be deterred from developing new products in a class or testing older drugs for additional indications if they risk exposure to staggering liability damages such as those facing Merck over its once-popular pain drug Vioxx, experts say.